Gemzar Articles
Amgen halts ganitumab study on little hope of success
9 August 2012
Increased uptake of FOLFIRINOX and launch of Abraxane will see dynamic change in treatment of pancreatic cancer patients
23 November 2010
US Appeal Court backs preliminary injunction against Apotex over AstraZeneca’s Pulmicort Respules; rejects Eli Lilly’s Gemzar appeal
3 November 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Eli Lilly outlines innovation strategy, sets 2010 financial guidance, but disappoints Wall Street
11 December 2009
Clavis Pharma and Clovis Oncology sign $380 million deal for anti-cancer agent CP-4126
26 November 2009
Seattle Genetics slumps on stopping dacetuzumab Phase IIb diffuse large B-cell lymphoma trial
6 October 2009
Sanofi-Aventis and Regeneron discontinue one Ph III study of aflibercept
14 September 2009
Lilly plans to appeal over Gemzar's intellectual property
7 September 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
Actavis expands into Irish market
23 March 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Prasugrel gets nod from CHMP
12 January 2009
Lilly swings into loss in 3rd qtr on legal costs
3 November 2008
Seattle Genetics highlights Ab-drug conjugate programs
3 November 2008
Lilly gets third appro for Alimta
6 October 2008
Alimta boosts survival in certain NSCLC types
9 June 2008
Strong apoptosis animal data for triphendiol
21 April 2008
EMEA clears histology-based use for Alimta
21 April 2008
New histology-based use for Alimta
3 March 2008
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Lymphoma drug gets EU Orphan Status
1 October 2007
Lilly files Alimta with EMEA for NSCLC
1 October 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
Teva sales forecast to reach $13.3B by 2010
16 July 2007
Lilly reports benefits of Alimta in NSCLC
11 June 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Eli Lilly Japan's 2006 sales up 7% to $700M
2 April 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
EC clears Roche's Tarceva in pancreatic cancer
5 February 2007
Roche/Genentech
15 January 2007
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Promising metastasis data for SR's Atu027 RNAi
11 December 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
Lilly's Gemzar wins 4th US cancer indication
24 July 2006
Lilly's enzastaurin: good combo drug at Ph I
12 June 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Australian PBS adds 45 drugs, widens use for 28
8 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Cell Thera's Xyotax sees strong Ph III results
18 July 2005
Eli Lilly reports 84% income rise in 1st qtr
25 April 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Lack of candidate drugs constraining bladder cancer Rx mkt
13 December 2004
Gemzar combination with Taxol OKed in UK
13 December 2004
Eli Lilly's income up 6% for 3rd-qtr 2004
1 November 2004
New Phase III results indicate versatility of Tarceva in treating range of cancers
27 September 2004
New use for Gemzar OKed in Europe
9 August 2004
FDA OKs Lilly's Gemzar for additional use
24 May 2004
Lilly sees sales climb 17% for 1st-qtr 2004
26 April 2004
Strong 2003 sales for Lilly but profits flat
9 February 2004
Stock Commentary - New York
13 October 2003
Zyprexa lifts Eli Lilly above estimates
4 August 2003
Lilly's Gemzar cleared for breast cancer
30 June 2003
Underlying growth beats forecasts at Lilly
28 April 2003
Lorus expands Virulizin Phase III trial
28 April 2003
Vion starts second Ph II trial of Triapine
10 February 2003
2003 will fall below forecast, says Eli Lilly
10 February 2003
Cyclacel's cancer drug starts Phase II testing
27 January 2003
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
J&J drug ineffective in GI cancers
27 May 2002
Alimta: first effective mesothelioma drug
27 May 2002
Lilly starts pivotal trial of antisense NSCLC drug
29 April 2002
MGI hit hard as cancer drug trial is stopped
22 April 2002
Emerging therapies for pancreatic cancer
18 February 2002
Eli Lilly earnings take a tumble
28 January 2002
AstraZeneca and Lilly collaborate on Iressa and Gemzar
7 January 2002
AstraZeneca and Lilly collaborate on Iressa and Gemzar
21 December 2001
Eli Lilly adding 5,000 more sales reps
26 October 2001
Lilly's pemetrexed in mesothelioma
26 October 2001
OSI starts additional trials of anti-EGFr drug
25 October 2001
Net oncome down 7% at Lilly
18 October 2001
Vion begins Ph I triapine/gemcitabine trials
3 August 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
New drugs lift Lilly's 2nd qtr sales 16%
20 July 2001
MGI initiates Phase I irofulven/Gemzar trial
21 June 2001
Lilly's Gemzar as a breast cancer treatment
22 May 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
